8 results on '"Scarsi, Mirko"'
Search Results
2. Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis.
- Author
-
Airo’, Paolo, Scarsi, Mirko, Rossi, Mara, and Mondini, Michele
- Subjects
- *
SYSTEMIC scleroderma , *ADRENOCORTICAL hormones , *CHRONIC kidney failure , *PUBLIC health , *MEDICAL research , *MULTIPLE sclerosis treatment , *PATIENTS - Abstract
The coexistence of systemic sclerosis (SSc) and multiple sclerosis (MS) in the same patient has been described in few cases. We refer here a further case of association between these diseases, which highlight the difficulty of treating such patients. A 57-year-old male with relapsing-remitting MS since 20 years, shortly after having received high-dose corticosteroids for a relapse of MS, suddenly developed SSc, with onset of Raynaud phenomenon simultaneous to that of scleroderma skin involvement, new appearance of accelerated arterial hypertension, and rapidly progressive oliguric renal failure, indicative of scleroderma renal crisis, that was controlled with ramipril, irbesartan and amlodipin. A further disabling relapse of MS was treated with interferon-beta, but 19 months later he developed multiple severe digital necrotic ulcers, that resolved with interferon discontinuation and therapy with iloprost. This case report shows that some form of treatment useful for MS might enhance the manifestations of SSc. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
3. Flow cytometry test to screen for HLA-B*58:01-associated allopurinol hypersensitivity.
- Author
-
Scarsi, Mirko, Bosio, Carla, Coccoli, Silvia, Barucco, Amilcare, Tavelli, Giovanna, and Airò, Paolo
- Subjects
- *
MEDICAL screening , *FLOW cytometry , *DRUG side effects , *ALLOPURINOL , *ANTIGENS , *RHEUMATOLOGY - Abstract
A strong association between the human leucocyte antigen (HLA)-B*58:01 allele and allopurinol-associated severe cutaneous adverse reactions (SCAR) has been reported. A screening for HLA-B*58:01 before allopurinol has been suggested in guidelines for management of gout. HLA-B*58:01 screening is generally based on molecular biology methods that may be not suitable for wide application. We have retrospectively evaluated the performance on a rapid flow cytometry (FCM) test, based on the use of a monoclonal antibody specific for HLA-B17, an antigen that can be split into HLA-B*57 and -B*58 alleles by molecular biology testing, which is used to screen for HLA-B*57:01 before prescription of the antiretroviral agent abacavir in HIV-positive patients. Among 475 samples that were analysed by FCM and by molecular biology test as gold standard, 2 out of 89 false negative tests for HLA-B*58:01 were found. The sensitivity was 97.8 % and the negative predictive value was 98.9 %. We have shown that a FCM test can identify almost all HLA-B*58:01 positive individuals. As FCM laboratories are more widely available than molecular biology ones, this approach could be used to reduce the risk for allopurinol-induced SCAR. Where both facilities are available, a two-step strategy (FCM as screening, molecular biology for confirmation) may reduce the cost of the screening. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
- Author
-
De Ciuceis, Carolina, Agabiti-Rosei, Claudia, Rossini, Claudia, Caletti, Stefano, Coschignano, Maria Antonietta, Ferrari-Toninelli, Giulia, Ragni, Giorgio, Cappelli, Carlo, Cerudelli, Bruno, Airò, Paolo, Scarsi, Mirko, Tincani, Angela, Porteri, Enzo, and Rizzoni, Damiano
- Subjects
- *
ANTIGEN analysis , *EPITHELIAL cells , *STEM cells , *INCRETINS , *BLOOD pressure measurement , *CELL receptors , *FINGERS , *FLOW cytometry , *HYPEREMIA , *MICROSCOPY , *NEOVASCULARIZATION , *TYPE 2 diabetes , *VOLUMETRIC analysis , *BODY mass index , *TREATMENT effectiveness , *EXENATIDE , *GLUCAGON-like peptide-1 agonists , *THERAPEUTICS , *PHYSIOLOGY , *CELL physiology - Abstract
Introduction: Glucagon-like peptide 1-receptor agonists (incretin mimetics) and dipeptidyl peptidase-4 inhibitors (incretin enhancers) have been recently introduced in the treatment of diabetes mellitus. In particular, incretin mimetics seems to have ancillary antioxidant/antinflammatory properties that might be involved in endothelial protection.Aim: To investigate the effect of incretin mimetic therapy (liraglutide, exenatide) given to 11 patients with type 2 diabetes mellitus, on circulating endothelial progenitor cells (EPCs) (bone marrow-derived cells possibly participating in neovascularization and endothelial protection and repair) and capillary density.Methods: Four diabetic patients were treated with exenatide (5 μg twice daily for 4 weeks and then 10 μg twice daily for 3 weeks) and 7 with liraglutide (0.6 mg per day for 1 week and then 1.2 mg per day for 3 weeks). Peripheral venous blood samples were obtained before treatment (basal) and after 4 week in patients treated with liraglutide, and after 4 and 7 weeks in patients treated with exenatide, since drug titration is usually longer. EPCs were evaluated by flow cytometry as CD34+/KDR+ cells. Capillary density was evaluated by videomicroscopy, before and after venous congestion, in the dorsum of the 4th finger.Results: Patients treated with liraglutide (6 males 1 female, age 54 ± 12 years) showed a decrease in body mass index and blood pressure during treatment, while patients treated with exenatide (3 males 1 female, age 57 ± 6 years) did not show any relevant change. EPCs were significantly increased after treatment with exenatide, but not after treatment with liraglutide. Capillary density was slightly increased only after 4 weeks of treatment with exenatide, however the increase was no longer present at the final evaluation.Conclusions: Treatment with exenatide, but not with liraglutide, was able to increase the number of circulating EPCs, possibly through an antioxidative/antiinflammatory effect. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis.
- Author
-
Piantoni, Silvia, Colombo, Enrico, Tincani, Angela, Airò, Paolo, and Scarsi, Mirko
- Subjects
- *
ABATACEPT , *RHEUMATOID arthritis , *BIOMARKERS , *MULTIVARIATE analysis , *LYMPHOCYTES - Abstract
The aim of this paper was to look for predictors of abatacept (ABA) therapy discontinuation in patients with rheumatoid arthritis (RA). Seventy-one RA patients treated with ABA were followed up. Demographical, clinical, and laboratory parameters of the patients, including peripheral blood T and B cell populations, different rheumatoid factor and anti-cyclic citrullinated peptide autoantibodies isotypes, and serum free light chains were evaluated. Comparing patients who discontinued ABA with those still in therapy we observed: a higher proportion of smokers (51.9 vs 25.6 %; p = 0.03); a non significant lower proportion of anti-cyclic citrullinated peptide positivity (76 vs 89.5 %; p = 0.13); a lower proportion of terminally differentiated effector memory cells (TDEM) among total CD8+ T lymphocytes at baseline (22.0 % (7.8-39.2) vs 38.7 % (20.7-55.9); p = 0.002). Logistic multivariate analysis showed that only the proportion of CD8+TDEM T cells was an independent predictive factor of therapy discontinuation (OR (95 % IC) = 6.2 (1.2 to 30.8); p = 0.026). Receiver-operating characteristic analysis showed a significant performance of this biomarker for prediction of therapy discontinuation (using a cut-off of 30.6 %: AUC: 0.760 ± 0.07; p = 0.002). Patients with a low proportion of CD8+TDEM at baseline had a higher probability of discontinuing the treatment during time (log-rank test: p < 0.01). T cell characterization for identification of TDEM CD8+ T cells might be a useful test to predict discontinuation of ABA therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.
- Author
-
Piantoni, Silvia, Colombo, Enrico, Airò, Paolo, Tincani, Angela, Brucato, Antonio, Franceschini, Franco, Andreoli, Laura, Furloni, Roberto, and Scarsi, Mirko
- Subjects
- *
COVID-19 , *ANGIOTENSIN converting enzyme , *CYTOKINE release syndrome - Published
- 2020
- Full Text
- View/download PDF
7. Thymic and Bone Marrow Output in Patients with Common Variable Immunodeficiency.
- Author
-
Serana, Federico, Airò, Paolo, Chiarini, Marco, Zanotti, Cinzia, Scarsi, Mirko, Frassi, Micol, Lougaris, Vassilios, Plebani, Alessandro, Caimi, Luigi, and Imberti, Luisa
- Subjects
- *
BONE marrow , *IMMUNODEFICIENCY , *T cell receptors , *B cells , *DIAGNOSTIC use of polymerase chain reaction , *DIAGNOSTIC use of flow cytometry , *PATIENTS - Abstract
Objective: The study aims to obtain more information about the immune deficit of common variable immunodeficiency (CVID) patients. Materials and Methods: A new real-time PCR assay was used to quantify T and B lymphocyte mobilization from the production and maturation sites through the detection of T cell receptor excision circles (TRECs) and kappa-deleting recombination circles (KRECs) and to allow the estimation of the average number of B cell divisions. T and B lymphocyte subsets were analyzed by flow cytometry. Results: The number of TREC lymphocytes, which depends on age and gender, was significantly reduced in CVID patients. Similarly, KREC concentration was lower than in controls. Classification of patients according to the percentage of memory switched B cells showed that patients belonging to MB2 group and therefore with conserved B cell maturation have the lowest new B cell output but increased average peripheral divisions, leading to the highest B cell number. Conclusions: TREC and KREC quantification can be helpful for a more complete and informative understanding of a heterogeneous disease such as CVID. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
8. An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility.
- Author
-
Antonioli, Chiara M., Bua, Giovanni, Frigè, Anna, Prandini, Katia, Radici, Sara, Scarsi, Mirko, Danieli, Elisabetta, Malvicini, Andrea, and Airo, Paolo
- Subjects
- *
SYSTEMIC scleroderma , *QUALITY of life , *ACTIVITIES of daily living training , *MEDICAL rehabilitation , *CONNECTIVE tissue diseases , *RESPIRATORY diseases , *PHYSICAL education - Abstract
Few data are available to assess the efficacy of rehabilitative interventions in systemic sclerosis (SSc). We refer here the results of an individualized rehabilitation program in 16 patients with SSc. In particular, when possible, the number of patients who achieved a minimal clinically important difference (MCID) was determined. Results were evaluated taking advantage of the development of validated questionnaires and tests to assess quality of life (QOL) and disability in SSc. At the end of a period of 4 months of observation, 69% and 62% of patients reported an improvement of the physical and mental components of the SF-36 higher than the MCID (as established in other rheumatic conditions). Analogously, an improvement of the impact of respiratory disease on patients’ QOL, as assessed by the Saint George’s Respiratory Questionnaire, was perceived by 67% of them. These results might be explained by better exercise tolerance, which was suggested by the significant reduction of the heart rate and of a visual analogue scale for dyspnoea at the end of the 6-min walking test. Finally, a statistically significant improvement of hand mobility, as assessed by the hand mobility in scleroderma test was obtained. This study suggests that a significant proportion of patients with SSc experience an improvement in their perception of QOL, a better exercise tolerance, and a better hand mobility after a rehabilitation program consisting by a 2-week period of daily individual 30-min sessions as outpatient, followed by at-home exercise program. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.